Drugs in development: bisphosphonates and metalloproteinase inhibitors.
The destruction of bone and cartilage is characteristic of the progression of musculoskeletal diseases. The present review discusses the developments made with two different classes of drugs, the bisphosphonates and matrix metalloproteinase inhibitors. Bisphosphonates have proven to be an effective and safe treatment for the prevention of bone loss, especially in osteoporotic disease, and may have a role in the treatment of arthritic diseases. The development of matrix metalloproteinase inhibitors and their role as potential therapies are also discussed, especially in the light of the disappointing human trials data so far published.
Catterall
Jon B
JB
Department of Rheumatology, The Medical School, University of Newcastle upon Tyne, UK.
Cawston
Tim E
TE
D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D001862:Bone Resorption; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010024:Osteoporosis / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use* / Q000633:toxicity
D004164:Diphosphonates; D011480:Protease Inhibitors; D008666:Metalloendopeptidases